Apollomics, Inc. (APLM)
NASDAQ: APLM · Real-Time Price · USD
5.49
-0.19 (-3.35%)
At close: May 9, 2025, 4:00 PM
5.65
+0.16 (2.91%)
After-hours: May 9, 2025, 4:26 PM EDT
Apollomics Revenue
In the year 2024, Apollomics had annual revenue of $198.00K, down -75.88%. Apollomics had revenue of $-1.57M in the half year ending December 31, 2024, with 477.21% growth.
Revenue (ttm)
$198.00K
Revenue Growth
-75.88%
P/S Ratio
29.26
Revenue / Employee
$15,231
Employees
13
Market Cap
6.06M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 198.00K | -623.00K | -75.88% |
| Dec 31, 2023 | 821.00K | 498.00K | 154.18% |
| Dec 31, 2022 | 323.00K | 321.00K | 16,050.00% |
| Dec 31, 2021 | 2.00K | -1.84M | -99.89% |
| Dec 31, 2020 | 1.84M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
APLM News
- 5 weeks ago - Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress - GlobeNewsWire
- 5 weeks ago - Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib - GlobeNewsWire
- 5 months ago - Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia - GlobeNewsWire
- 5 months ago - Apollomics Regains Compliance with Nasdaq's Minimum Bid Price Requirement - GlobeNewsWire
- 8 months ago - Apollomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewsWire
- 9 months ago - Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical Progress - GlobeNewsWire
- 9 months ago - Apollomics Announces Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from its Phase 2 SPARTA Trial - GlobeNewsWire
- 10 months ago - Apollomics Granted 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Requirement - GlobeNewsWire